drugset
drugset / Trial / NCT07106736

MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma

NCT07106736 ↗

Phase 2 Recruiting 60 enrolled Institute of Hematology & Blood Diseases Hospital, China
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.

Timeline

Start
2025-08-10
Primary completion
2027-08-01
Completion
2029-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BCMA CAR-T Cell therapy 3e+06 cells/kg —

Indications

plasma cell myeloma